Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 3.22
CUR's Cash to Debt is ranked lower than
67% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. CUR: 3.22 )
Ranked among companies with meaningful Cash to Debt only.
CUR' s 10-Year Cash to Debt Range
Min: 1.47  Med: 9999.50 Max: No Debt
Current: 3.22
Equity to Asset 0.63
CUR's Equity to Asset is ranked lower than
57% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CUR: 0.63 )
Ranked among companies with meaningful Equity to Asset only.
CUR' s 10-Year Equity to Asset Range
Min: -0.81  Med: 0.69 Max: 0.93
Current: 0.63
-0.81
0.93
F-Score: 2
Z-Score: 0.15
M-Score: -3.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -93733.33
CUR's Operating margin (%) is ranked lower than
98% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. CUR: -93733.33 )
Ranked among companies with meaningful Operating margin (%) only.
CUR' s 10-Year Operating margin (%) Range
Min: -91768.42  Med: -2081.05 Max: -507.12
Current: -93733.33
-91768.42
-507.12
Net-margin (%) -120900.00
CUR's Net-margin (%) is ranked lower than
98% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. CUR: -120900.00 )
Ranked among companies with meaningful Net-margin (%) only.
CUR' s 10-Year Net-margin (%) Range
Min: -119100  Med: -2480.88 Max: -534.63
Current: -120900
-119100
-534.63
ROE (%) -99.91
CUR's ROE (%) is ranked lower than
81% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. CUR: -99.91 )
Ranked among companies with meaningful ROE (%) only.
CUR' s 10-Year ROE (%) Range
Min: -1295.32  Med: -246.11 Max: -147.69
Current: -99.91
-1295.32
-147.69
ROA (%) -68.59
CUR's ROA (%) is ranked lower than
78% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. CUR: -68.59 )
Ranked among companies with meaningful ROA (%) only.
CUR' s 10-Year ROA (%) Range
Min: -481.63  Med: -174.29 Max: -91.88
Current: -68.59
-481.63
-91.88
ROC (Joel Greenblatt) (%) -6689.16
CUR's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. CUR: -6689.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CUR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -10806.9  Med: -7755.83 Max: -3877.01
Current: -6689.16
-10806.9
-3877.01
Revenue Growth (3Y)(%) -100.00
CUR's Revenue Growth (3Y)(%) is ranked lower than
98% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. CUR: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CUR' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -100.00 Max: 26
Current: -100
0
26
EBITDA Growth (3Y)(%) -2.60
CUR's EBITDA Growth (3Y)(%) is ranked higher than
51% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. CUR: -2.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CUR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -17.2  Med: -6.60 Max: 35.7
Current: -2.6
-17.2
35.7
» CUR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with CUR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.75
CUR's P/B is ranked lower than
71% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. CUR: 7.75 )
Ranked among companies with meaningful P/B only.
CUR' s 10-Year P/B Range
Min: 3.74  Med: 11.87 Max: 64
Current: 7.75
3.74
64
P/S 8313.92
CUR's P/S is ranked lower than
180% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. CUR: 8313.92 )
Ranked among companies with meaningful P/S only.
CUR' s 10-Year P/S Range
Min: 0  Med: 164.00 Max: 451
Current: 8313.92
0
451
Current Ratio 6.72
CUR's Current Ratio is ranked higher than
62% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. CUR: 6.72 )
Ranked among companies with meaningful Current Ratio only.
CUR' s 10-Year Current Ratio Range
Min: 0.52  Med: 4.33 Max: 16.97
Current: 6.72
0.52
16.97
Quick Ratio 6.72
CUR's Quick Ratio is ranked higher than
63% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CUR: 6.72 )
Ranked among companies with meaningful Quick Ratio only.
CUR' s 10-Year Quick Ratio Range
Min: 0.52  Med: 4.33 Max: 16.97
Current: 6.72
0.52
16.97
Days Sales Outstanding 162.22
CUR's Days Sales Outstanding is ranked lower than
87% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. CUR: 162.22 )
Ranked among companies with meaningful Days Sales Outstanding only.
CUR' s 10-Year Days Sales Outstanding Range
Min: 2.68  Med: 125.81 Max: 4341.58
Current: 162.22
2.68
4341.58

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.74
CUR's Price/Net Cash is ranked lower than
54% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. CUR: 8.74 )
Ranked among companies with meaningful Price/Net Cash only.
CUR' s 10-Year Price/Net Cash Range
Min: 7.79  Med: 15.24 Max: 60
Current: 8.74
7.79
60
Price/Net Current Asset Value 8.30
CUR's Price/Net Current Asset Value is ranked lower than
55% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. CUR: 8.30 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CUR' s 10-Year Price/Net Current Asset Value Range
Min: 7.79  Med: 15.18 Max: 96.5
Current: 8.3
7.79
96.5
Price/Tangible Book 8.30
CUR's Price/Tangible Book is ranked lower than
64% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. CUR: 8.30 )
Ranked among companies with meaningful Price/Tangible Book only.
CUR' s 10-Year Price/Tangible Book Range
Min: 7.4  Med: 14.44 Max: 60
Current: 8.3
7.4
60
Earnings Yield (Greenblatt) (%) -15.90
CUR's Earnings Yield (Greenblatt) (%) is ranked lower than
73% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. CUR: -15.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CUR' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -15.9  Med: 0.00 Max: 0
Current: -15.9
-15.9
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:7NS.Germany,
Neuralstem Inc was incorporated in 1996 in the state of Maryland. In 2001 it re-incorporated in the state of Delaware. It is engaged in development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs. The Company has developed and also maintains a portfolio of patents and patent applications that form the proprietary base of its research and development efforts in the area of neural stem cell research, and related technologies. Its technology base, in combination with its know-how, and collaborative projects with research institutions, provide a competitive advantage and would facilitate the successful development and commercialization of products for use in treatment of an array of neurodegenerative conditions and in regenerative repair of acute disease. The Company is focused on leveraging its key assets, including its intellectual property, its scientific team, its facilities and its capital, to accelerate the advancement of its stem cell technologies. In addition, it is pursuing strategic collaborations with members of academia. The Company manufactures its cells both in-house and on an outsource basis. It uses these cells in its research and collaborative programs. It outsources all the manufacturing and storage of its stem cells to be used in pre-clinical works, and which are accordingly subject to higher FDA requirements, to Charles River Laboratories, Inc., of Wilmington, Massachusetts. The Company's competitors include multinational pharmaceutical companies, specialty biotechnology companies and chemical and medical products companies operating in the fields of regenerative medicine, cell therapy, tissue engineering and tissue regeneration. Many of these companies are well-established and possess technical, research and development, financial and sales and marketing resources greater than the Company. The Company is subject to U.S. federal, state, local and international laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its business.
» More Articles for CUR

Headlines

Articles On GuruFocus.com
Neuralstem Inc. Reports Operating Results (10-Q) Nov 15 2010 
View on CUR Sep 11 2010 
Neuralstem Inc. Reports Operating Results (10-Q) Aug 16 2010 
Neuralstem Inc. Reports Operating Results (10-Q) May 17 2010 
Weekly CFO Buys Highlight: Neuralstem Inc., Converted Organics Inc., Princeton National Bancorp Inc. Jan 09 2010 
Weekly CEO Buy Highlights: Helix Energy Solutions Group Inc, Neuralstem Inc, Saul Centers Inc, Casua Jan 09 2010 
Weekly CFO Buy Highlights: Neuralstem Inc., New Generation Biofuels Holdings, Converted Organics, Or Jan 04 2010 
Neuralstem Inc. Reports Operating Results (10-Q) Nov 16 2009 
Neuralstem Inc. Reports Operating Results (10-Q) Aug 14 2009 

More From Other Websites
StemCells to Rebound From Suit Dismissal Jul 24 2015
NEURALSTEM, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 23 2015
6 Stocks Under $10 Triggering Breakout Trades Jul 23 2015
US District Court Rules In Favor Of Neuralstem In Patent Infringement Case Jul 23 2015
US District Court Rules In Favor Of Neuralstem In Patent Infringement Case Jul 23 2015
NEURALSTEM, INC. Financials Jul 16 2015
curasan presents strategic outlook for 2016 Jul 03 2015
Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market Jun 29 2015
NEURALSTEM, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing... Jun 29 2015
Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market Jun 29 2015
NEURALSTEM, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 26 2015
Friday's Mid-Day Movers: Micron, Winnebago, Cleveland BioLabs And More Jun 26 2015
Neuralstem, Inc. (CUR)’s Shares Opened 4.83% Higher On Preclinical Alzheimer’s Data Jun 26 2015
Preclinical Data On Neuralstem's Genetically Modified HK532-IGF-1 Stem Cells In Alzheimer's Disease... Jun 26 2015
Preclinical Data On Neuralstem's Genetically Modified HK532-IGF-1 Stem Cells In Alzheimer's Disease... Jun 26 2015
NEURALSTEM, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 22 2015
curasan and Stryker overcome commercial differences Jun 22 2015
10-Q for Neuralstem, Inc. May 11 2015
NEURALSTEM, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events,... May 11 2015
NEURALSTEM, INC. Files SEC form 8-K, Results of Operations and Financial Condition May 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK